miRview® lung utilizes proprietary technology developed by Rosetta Genomics. This technology includes protocols for the extraction of microRNA from formalin-fixed paraffin-embedded (FFPE) tissue samples and quantification of the relative amount of the eight (8) microRNA biomarkers using quantitative real-time polymerase chain reaction (qRT-PCR) platform to differentiate patients with SCLS, carcinoid, squamous NSCLC and non-squamous NSCLC.

 

miRview® lung is the product of 2 years of research with hundreds of tumor samples. In the first phase of development, more than 100 tumor samples were studied by high-throughput molecular profiling¹, using microRNA microarrays to identify the molecular markers differentiating between the four main types of lung cancer. In the second phase, the microRNA markers were validated and a diagnostic assay was defined using sensitive and specific proprietary qRT-PCR technology. The accuracy of miRview® lung was demonstrated in an independent study². The sensitivity and specificity of miRview® lung assay were determined to be 93.7% and 98%, respectively.

 

Although many current cancer tests are largely qualitative and subjective, the measurement of microRNA expression levels in tissue samples offers a quantitative, objective diagnosis. Proprietary technologies enable microRNA profiling with high sensitivity and specificity. MicroRNA can be detected in small quantities in a high throughput manner. In addition, microRNAs are stable markers in many body fluids and tissue samples, making them an ideal platform for molecular diagnostics.

 

1. Rosenfeld N, Aharonov R, Meiri E, et al. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol. 2008;26(4):462-469.
2. Data on file, Rosetta Genomics